TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14715050
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs (specific drugs not mentioned)
Study: 14715050
Drug: High-potency antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency antipsychotics coadministered with inhibitors such as clarithromycin
Study: 3288683
Drug: Ketotifen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (2 mg, three doses over 14 hours)
Study: 3288683
Drug: Ketotifen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (200 ng intradermal PAF)
Study: 31036048
Drug: Endoscopic sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sinus surgery (ESS) plus intranasal medication
Study: 31036048
Drug: Clarithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (250 mg) plus intranasal medication
Study: 31036048
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus intranasal medication
Study: 21988668
Drug: 3-week titration
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week titration (weekly quarter-dose increments over 3 weeks to full dose [30 µg])
Study: 21988668
Drug: 6-week titration
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-week titration (biweekly quarter-dose increments over 6 weeks to full dose)
Study: 21988668
Drug: No titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No titration (full dose over 8 weeks)
Study: 16532500
Drug: Decitabine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (15 mg/m2 intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks)
Study: 12684288
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled fluticasone (880 micro g/d) for 28 days
Study: 9689201
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens 0.625 mg/day for 21 days plus chlormadinone 2 mg for the last 12 days (Group I)
Study: 9689201
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens 0.625 mg/day plus chlormadinone 1 mg/day, continuous and uninterrupted (Group II)
Study: 8126242
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser followed by air‐powder abrasive treatment
Study: 2671559
Drug: Daily rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rifampicin (600 mg), ethionamide (500 mg), and dapsone (100 mg) or clofazimine (100 mg) for 8 weeks followed by once weekly rifampicin (600 mg) and daily ethionamide (500 mg) and dapsone (100 mg) or clofazimine (100 mg) for 44 weeks
Study: 791442
Drug: Streptokinase (2,500,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (2,500,000 IU intravenous infusion over 24 hours)
Study: 31665326
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment at 67 µg/kg/day for 1 year
Study: 25398590
Drug: Fibrin-sealant-delivered cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fibrin-sealant-delivered cisplatin chemotherapy (FS)
Study: 25398590
Drug: Cisplatin hyperthermic
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin hyperthermic intraperitoneal perfusion chemotherapy (CHIC)
Study: 21146267
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention (3 educational seminars, assistance with action plans, monthly monitoring)
Study: 17050042
Drug: High-titer varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer varicella vaccine (PUVV) - approximately 50,000 PFU
Study: 17050042
Drug: Lower-titer formulation
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-titer formulation of VARIVAX - approximately 5400 PFU
Study: 17050042
Drug: High-titer varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer varicella vaccine (PUVV)
Study: 12624290
Drug: Lower concentrations
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower concentrations of IL-10 (<6 pg/mL)
Study: 11008922
Drug: 25,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25,000 IU of retinol daily
Study: 9081107
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (11.4 gm)
Study: 9081107
Drug: Insulin solution
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin solution (225 IU insulin, glucose with glucose clamp technique, and potassium) in addition to amino acid infusion
Study: 8382132
Drug: Dihydralazine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (7.5 mg)
Study: 8382132
Drug: Enalaprilat (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (1.25 mg)
Study: 31384411
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil supplementation (5 g of flaxseed oil containing 2.5 g α‐Linolenic acid)
Study: 31384411
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 ml of 1.5% fat milk)
Study: 30258212
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus zoledronic acid
Study: 22471362
Drug: Keishi-bukuryo-gan (3.75g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keishi-bukuryo-gan (3.75g twice daily for seven days)
Study: 20860913
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg every 4 weeks
Study: 18569471
Drug: Intravaginal Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal Misoprostol 25 microm 4‐hourly
Study: 18569471
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone 0.5 mg 12 hourly
Study: 15799717
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (80 mg of caffeine)
Study: 15799717
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (< 2 mg of caffeine)
Study: 12447087
Drug: Force-feedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Force-feedback treatment for lower paretic limb
Study: 12447087
Drug: Force-feedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Force-feedback treatment for upper paretic limb
Study: 6617596
Drug: Polytherapy (reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytherapy (reduction of anticonvulsants)
Study: 6617596
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum levels of anticonvulsants
Study: 6617596
Drug: Monotherapy (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (high serum levels)
Study: 29939243
Drug: 2-visit intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-visit intradermal vaccination (2 doses of 0.1 mL ID of HDCV at days 0 and 7)
Study: 29939243
Drug: 3-visit standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-visit standard vaccination (single dose of 0.1 mL ID at days 0, 7, and 28)
Study: 25428755
Drug: Ropivacaine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (7.5 mg/mL)
Study: 25428755
Drug: NaCl (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (9 mg/mL)
Study: 17309378
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (20 minutes of massage on five occasions)
Study: 11386490
Drug: d-amphetamine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (10-20 mg)
Study: 11386490
Drug: methylphenidate (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate (20-40 mg)
Study: 8187012
Drug: New pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New pharmaceutical agents
Study: 3046283
Drug: APSAC (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: APSAC (30 U as intravenous injection)
Study: 3046283
Drug: APSAC and
Normalized name: APSAC
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APSAC and Heparin
Study: 30721549
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (GH)
Study: 22999815
Drug: Printed literature
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Printed literature about alcohol and drug use risks (Control)
Study: 21701341
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound treatment at 59 J/cm
Study: 21701341
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound treatment at 47 J/cm
Study: 20175279
Drug: norbactin (norfloxacin)
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norbactin (norfloxacin) 400 mg twice a day for 7 days
Study: 20175279
Drug: furamag 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: furamag 50 mg 3 times a day for 10 days
Study: 16944396
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prednisolone (Pred)
Study: 16944396
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prednisolone plus 4 mg salbutamol (Pred-Sal)
Study: 2966140
Drug: Teicoplanin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (400 mg on induction of anaesthesia and 200 mg 24 h later)
Study: 2966140
Drug: Teicoplanin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (three doses of 400 mg)
Study: 2966140
Drug: Tobramycin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (80 mg tds for three days) and flucloxacillin (500 mg qds for 5 days)
Study: 30254744
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of medicine pill boards
Study: 27107960
Drug: Naprapathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprapathic manual therapy (spinal manipulation, spinal mobilization, stretching and massage)
Study: 27107960
Drug: Naprapathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprapathic manual therapy excluding spinal manipulation
Study: 27107960
Drug: Naprapathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprapathic manual therapy excluding stretching
Study: 27107960
Drug: Naprapathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprapathic manual therapy (all groups)
Study: 19218249
Drug: Nadolol +
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol + Isosorbide-5-mononitrate alone (Drug)
Study: 19218249
Drug: Nadolol +
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol + Isosorbide-5-mononitrate combined with EBL (Drug + EBL)
Study: 17204097
Drug: Serial glycolic
Normalized name: glycolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial glycolic acid peels, topical azelaic acid 20% cream (b.i.d.), and adapalene 0.1% gel (q.i.d.)
Study: 17204097
Drug: Topical azelaic
Normalized name: azelaic acid Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical azelaic acid and adapalene (control group)
Study: 12504397
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m(2) intravenously every 3 months for 24 months
Study: 12419743
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m(2)
Study: 10422931
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg neostigmine in the axillary plexus and saline solution subcutaneously (group 2)
Study: 10422931
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution in the axillary plexus and 500 microg neostigmine subcutaneously (group 3)
Study: 10422931
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution in the axillary plexus and subcutaneously (group 1)
Study: 401005
Drug: Papaverine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (150 mg BID for 1 week, then 300 mg BID for 5 weeks)
Study: 401005
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (6-week no drug control condition)
Study: 28413925
Drug: Triple-bead mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-bead mixed amphetamine salts (MAS) 25, 50, or 75 mg
Study: 28101779
Drug: Topical EMLA
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EMLA with breastfeeding (EB group)
Study: 28101779
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray with breastfeeding (VB group)
Study: 25136638
Drug: Omega-3 tablets
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 tablets (2.4 gr/day)
Study: 25136638
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E tablets (400 IU/day)
Study: 15338687
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol therapy (Group III)
Study: 15338687
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol therapy (Group II)
Study: 15338687
Drug: No calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcitriol therapy (Group I)
Study: 11229829
Drug: Garlic oil
Normalized name: Garlic Oil
DrugBank: Garlic oil (DB15989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic oil (GO) capsules, 12.3 mg/day for 16 weeks
Study: 7735929
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with clarithromycin (200 mg, three times a day) + sofalcone (100 mg, three times a day) for 3 weeks
Study: 7735929
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with clarithromycin (200 mg, three times a day) + sofalcone (100 mg, three times a day) for 2 weeks
Study: 7735929
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with clarithromycin + sofalcone
Study: 1976379
Drug: Terfenadine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 40 mg
Study: 1976379
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terfenadine 40 mg and pseudoephedrine 60 mg
Study: 380580
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of Bay g 5653
Study: 380580
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of Bay g 5653
Study: 380580
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of Bay g 5653
Study: 26096765
Drug: AZD6482 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6482 + aspirin
Study: 26096765
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (P2Y12 + PI3Kβ + COX‐1)
Study: 20598967
Drug: Clopidogrel +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel + aspirin
Study: 23497759
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating film (ODF) formulation of sildenafil, 50 mg (part 1)
Study: 23497759
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet (FCT) formulation of sildenafil, 50 mg (part 1)
Study: 23497759
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating film (ODF) formulation of sildenafil, 100 mg (part 2)
Study: 23497759
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet (FCT) formulation of sildenafil, 100 mg (part 2)
Study: 23497759
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events (AEs) with ODF and FCT formulations
Study: 18090169
Drug: N-acetylcysteine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (1200 mg every 12 hrs, starting immediately before cardiac surgery)
Study: 15200747
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CT) with nateglinide (120 mg, ac) and metformin (500 mg, tid)
Study: 11115582
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with TAI of 120 mg/body cisplatin twice a month at 4-week intervals
Study: 11115582
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with 200 mg/day oral 5‐FU or UFT every day
Study: 9600369
Drug: Tamoxifen, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen, 40 mg/day
Study: 7993983
Drug: Benazepril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (20 mg)
Study: 7993983
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of aspirin and benazepril
Study: 31669225
Drug: Preventive inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive inhalation of hypertonic saline
Study: 19725815
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium ophthalmic solution (BF)
Study: 19725815
Drug: Steroidal solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroidal solution (ST)
Study: 17428949
Drug: Monovalent HPV16
Normalized name: rotavirus, monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent HPV16 vaccine
Study: 15797982
Drug: Proparacaine HCl
Normalized name: proparacaine HCl
DrugBank: Proparacaine (DB00807)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proparacaine HCl ophthalmic solution 0.5%
Study: 9583551
Drug: Etomidate, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate, 0.3 mg/kg, and fentanyl, 1 microg/kg
Study: 9583551
Drug: Ketamine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine, 1 mg/kg, and fentanyl, 1 microg/kg
Study: 8580227
Drug: CI-988 capsules/CCK-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-988 capsules/CCK-4
Study: 8580227
Drug: Placebo capsules/CCK-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules/CCK-4
Study: 8580227
Drug: Placebo capsules/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules/placebo
Study: 2679240
Drug: L-carnitine, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine, 3 g IV as a bolus, followed by continuous intravenous infusion of 2 mg/kg/min for thirty minutes
Study: 27865117
Drug: Intraaortic balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraaortic balloon pump therapy
Study: 25859764
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT-SAD) for 6 weeks, 12 sessions in a group format, 90 minutes each, administered by Ph.D. psychologists
Study: 25859764
Drug: Light Therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light Therapy for 6 weeks, 10,000-lux cool-white fluorescent light, initiated at 30 minutes each morning
Study: 18947437
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (0-2 g/d) for up to 10 weeks
Study: 17725415
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) once daily (QD)
Study: 17725415
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) twice daily
Study: 11728950
Drug: Prednisolone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.8 mg/kg/d) for 1 month
Study: 8435260
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg‐1 and alfentanil 10 micrograms kg‐1
Study: 8435260
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg‐1, alfentanil 10 micrograms kg‐1, and lignocaine 1 mg kg‐1
Study: 8435260
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg‐1 and alfentanil 20 micrograms kg‐1
Study: 8435260
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg‐1, alfentanil 20 micrograms kg‐1, and lignocaine 1 mg kg‐1
Study: 21182491
Drug: Buprenorphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (20 µg·h(‐1), 144 h)
Study: 21182491
Drug: Fentanyl (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (25 µg·h(‐1), 72 h)
Study: 17165496
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine Paishi Decoction, 40 mL of 33% magnesium sulfate, 30 mL of 0.5% hydrochloric acid, fat diet, and Tuian Yunjing Instrument
Study: 10765962
Drug: DMPS (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPS (2 mg/kg body weight) injected intravenously
Study: 9050975
Drug: Sustained-release verapamil/trandolapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil/trandolapril